Trial Profile
A Prospective, Multisite Study to Evaluate the Impact of Measles, Mumps, Rubella and Varicella ProQuad Vaccination in Pediatric Patients 6-24 Months of Age Who Are Being Considered and/or Evaluated for Any Solid Organ Transplant
Status:
Completed
Phase of Trial:
Phase 0
Latest Information Update: 18 Feb 2019
Price :
$35
*
At a glance
- Drugs MMR-varicella zoster virus vaccine (Primary)
- Indications Measles; Mumps; Rubella; Varicella zoster virus infections
- Focus Pharmacodynamics
- 08 Feb 2019 Status changed from recruiting to completed.
- 05 May 2018 Planned End Date changed from 1 Jan 2018 to 1 Dec 2018.
- 05 May 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2018.